20260701-31 Listing of Equity Shares of Allcargo Global Limited (Formerly known as Allcargo Worldwide Limited and originally incorporated as Allcargo Ecu Limited) Equity Company related Listing Operations

Inter alia, to consider and approve the appointment of Mr. Bidari Kotresh Anilkumar as an Additional Director (Executive) designated as Executive Director of the Company.

Employees Stock Option Plan Inter alia, approved :- A. CHANGE IN BOARD OF DIRECTORS: Upon recommendation of the Nomination & Remuneration Committee ( NRC ), subject to approval of the shareholders of the Company, the Board approved the following appointments of Directors with effect from 1 July 2026, pursuant to the implementation of the Scheme of Amalgamation and consequent changes in the organizational structure and management framework of the merged entity:- i. Appointment of Mr. Varun Khanna (DIN:03584124) as an Additional Director, Designated as Managing Director & Group Chief Executive Officer (Key Managerial Personnel) of the Company for a term of five (5) years. ii. Appointment of Mr. Neeraj Jain (DIN: 00348591), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. iii. Appointment of Mr. Kewal Handa (DIN: 00056826), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. iv. Appointment of Mr. V K Mathews (DIN: 00049414), as an Additional Director, designated as Independent Director of the Company for a period of three (3) years. v. Appointment of Ms. Ayshwarya Vikram (DIN: 08153649) as an Additional Director, designated as NonExecutive Director of the Company vi. Appointment of Mr. Ganesh Mani (DIN: 08385423) as an Additional Director, designated as NonExecutive Director of the Company. The above appointees have affirmed that they are not debarred from holding the office of director by virtue of any order of the Securities and Exchange Board of India or any other such authority B. RESIGNATION OF DIRECTORS i. Resignation of Mr. Maniedath Madhavan Nambiar(DIN: 01122411) and Mr. C. J. George (DIN: 00003132), as Independent Directors of the Company with effect from 1 July 2026. ii. Resignation of Dr. Zeba Azad Moopen (DIN: 03604401) and Mr. Shamsudheen Bin Mohideen Mammu Haji (DIN: 02007279) as Non-Executive Directors of the Company with effect from 1 July 2026. The above Directors have confirmed that there are no other material reasons for the resignation other than those mentioned in their respective resignation letters. The Details as required under the SEBI Master Circular dated 30 January 2026, with regard to appointment and resignation of Directors are provided as Annexure I and copy of the resignation letters of the Directors is enclosed as Annexure II with this letter. C. CHANGES IN COMMITTEE COMPOSITIONS Consequent to the above change in Directors, the Board re-constituted its Committees w.e.f. 01 July 2026. The revised composition of the Committees is enclosed as Annexure III to this letter. D. CHANGES IN THE SENIOR MANAGEMENT PERSONNEL ( SMP ) OF THE COMPANY ON ACCOUNT OF RESIGNATION The Board of Directors noted the resignation of Mr. Hitesh Dhaddha as Chief Investor Relations and M&A Officer with effect from close of business hours of 18 July 2026. The relevant details as required under the SEBI Master Circular dated 30 January 2026, are provided as Annexure IV and resignation letter of Ms. Hitesh Dhaddha are enclosed as Annexure V to this letter. ON ACCOUNT OF CHANGE IN ORGANISATIONAL STRUCTURE Consequent to the change in the organizational structure of the Company and pursuant to the Scheme, the Board of Directors approved the revised list of SMPs of the Company with effect from 1 July 2026, in terms of Regulation 16(1)(d) of the SEBI Listing Regulations, as follows: E. AMENDMENT TO ASTER DM HEALTHCARE LIMITED EMPLOYEE STOCK OPTION SCHEME 2026 Based on the recommendation of the Nomination and Remuneration Committee ( NRC ) vide its meeting held on July 1, 2026, and subject to the approval of the shareholders of the Company, the Board approved the amendments to the Aster DM Healthcare Limited Employee Stock Option Scheme 2026 ( ESOP Scheme 2026 ), which was previously considered and approved by the NRC and the Board at their respective meetings held on 29 January 2026 and 30 January 2026, details of which are specified below: a. Updated the name of the ESOP Scheme 2026 to Aster DM Quality Care Limited Employee Stock Option Scheme 2026 . b. The effective date of the ESOP Scheme 2026 has been updated to be the date on which the shareholders of the Company approve it. c. Grants under the ESOP Scheme 2026 (upon approval by the shareholders) are to be made to the eligible employees of the Company and its unlisted subsidiaries. d. Removal of provisions on re-pricing of options under the ESOP Scheme 2026. Please refer to the detailed disclosure set out in Annexure-VI to this letter for certain additional amendments to the ESOP Scheme 2026. All other terms of ESOP Scheme 2026 shall remain unchanged. Detailed disclosure as required under Regulation 30 of the Listing Regulations and SEBI Master Circular dated January 30, 2026, is annexed to this letter as Annexure-VI. F. Approved the change in designation of Ms. Alisha Moopen (DIN: 002432525) from Deputy Managing Director to Executive Director, with effect from 1 July 2026. G. Re-designated Dr. Azad Moopen (DIN: 000159403), Executive Chairman, and Ms. Alisha Moopen (DIN: 002432525), Executive Director, as Non-Key Managerial Personnel of the Company in terms of Section 203 of the Companies Act, 2013, with effect from 1 July 2026.

The Exchange has sought clarification from Esha Media Research Ltd on July 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.

The Exchange has sought clarification from Gulf Oil Lubricants India Ltd on July 01, 2026, with reference to Movement in Volume. The reply is awaited.

The Exchange has sought clarification from IITL Projects Ltd on July 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.

Submission of Letter of Offer for Buyback of equity shares of the Company

Clarification on Outlook for Q1FY27 and for the remainder of the year

The Exchange has sought clarification from Laxmipati Engineering Works Ltd on July 01, 2026, with reference to Movement in Price. The reply is awaited.

Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Shareholders of Niraj Cement Structurals Ltd ("Target Company").

The Exchange has sought clarification from Quess Corp Ltd on July 01, 2026, with reference to Movement in Volume. The reply is awaited.

Inter alia, to discuss and approve the following agenda: 1. To approve Directors Report along with its annexure for the financial year ended 31st March, 2026. 2. To approve and fix the day, date, time and venue of the Thirtieth Annual General Meeting (AGM) and approve the notice of convening of 31st AGM for the financial year 2025-26 and related matters thereto. 3. To appoint Mrs. Ushasree Bhagavatula (DIN: 11480507) as additional Independent Women Director on the Board of the Company. 4. Other items on agenda.

The Exchange has sought clarification from Schneider Electric President Systems Ltd on July 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.

Intimation dated 26th June, 2026 regarding Shareholder Meeting/ Postal Ballot - Scrutinizer Report) was inadvertently uploaded on BSE. The announcement was pertaining to another company.

The Exchange has sought clarification from Shah Foods Ltd on July 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.

Inter alia, to consider and approve the Appointment of an Independent Director

Rights Issue Inter alia, transacted the following items of business: a) Approved the appointment of Ms. Mehvish as Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, with effect from July 1, 2026. b) Approved the raising of funds, through issuance and allotment of equity shares having face value of Rs. 2 each up to an aggregate amount not exceeding ?12,000 Lakhs (Rupees Twelve Thousand Lakhs Only), on rights basis and on such terms (as decided by the Board, at a later date) to the eligible equity shareholders of the Company, as on the record date (to be notified subsequently), subject to receipt of regulatory/ statutory approvals, in accordance with the applicable laws including the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI Listing Regulations and the Companies Act, 2013, and rules and regulations made thereunder each as amended from time to time and approved other related matters to implement the proposal of Rights Issue. Further, for the purposes of giving effect to the rights issue, the specific and detailed terms in relation to the rights issue, including but not limited to the determination of the issue price, rights entitlement ratio, record date, timing of the rights issue and terms of payment will be determined by the Board and disclosed to the exchange in due course. c) The Company approved the draft letter of offer for the purpose of seeking in-principle approvals from BSE and NSE in relation to the proposed rights issue. The Board also approved other allied matters in relation to the draft letter of offer proposed to be filed with the Stock Exchange

Inter alia, to consider and approve :- 1. Appointment of Director(s) of the Company. 2. Increase in the Authorised Share Capital of the Company. 3. Fund-raising proposals, including by way of issue of equity shares and/or other eligible securities through one or more permissible modes, such as preferential issue, rights issues. 4. Any other business with the permission of the Chair.

The Exchange has sought clarification from Shri Niwas Leasing And Finance Ltd on July 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.

The Exchange has sought clarification from SMS Pharmaceuticals Ltd on July 01, 2026, with reference to Movement in Volume. The reply is awaited.